Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426865 · ClinicalTrials.gov registry record
Role of Axumin PET Scan in Germ Cell Tumor
A clinical trial of Germ Cell Tumor and Testicular Cancer, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT03426865: Completed study of Germ Cell Tumor and Testicular Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT03426865 is a study of Germ Cell Tumor and Testicular Cancer that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants, below the 347-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03426865, a study of Germ Cell Tumor and Testicular Cancer, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.
Primary Outcome
Investigate the accuracy of anti-18F-FACBC PET/CT correlating with histopathologic outcomes
Conditions Studied
Interventions
- DRUG Axumin PET scan
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2023-06-01 |
What the finished NCT03426865 record still lists
NCT03426865 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 347-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (97% lower).
The record links to 10 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Axumin PET scan is the first listed.
NCT03426865 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03426865 about?
NCT03426865 is a clinical study titled "Role of Axumin PET Scan in Germ Cell Tumor". Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.
What is the current status of trial NCT03426865?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2018-03-01. Estimated completion is 2023-06-01.
What conditions does trial NCT03426865 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Testicular Cancer, Testicular Germ Cell Tumor, Testis Cancer, Testicular Diseases.
What interventions are being tested in trial NCT03426865?
The interventions under investigation include: Axumin PET scan (DRUG).
Who is sponsoring clinical trial NCT03426865?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03426865 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03426865's enrollment target sits among peer trials
10 19th of 19 the lowest of 19 other Germ Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RECRUITING · Phase 3
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
Germ Cell Tumor and Testicular Tumor DNA Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI